All In Biotech

Free tool

FAERS Monitor: Beovu

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761125 or its brand name (Beovu, Brolucizumab-Dbll). Reports on generic versions are filed under their own applications.

Reports

3,648

Serious

2,878

79% of reports

Hospitalization

283

Death reported

246

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • visual impairment573
  • vitreous floaters558
  • vision blurred536
  • eye inflammation447
  • visual acuity reduced435
  • retinal vasculitis384
  • uveitis364
  • vitritis358
  • eye pain319
  • blindness247
  • anterior chamber cell233
  • ocular hyperaemia224
  • vitreous opacities223
  • drug ineffective221
  • keratic precipitates217

Reports by year received

View as table
YearReports
20161
20181
2019185
20201,252
2021845
2022461
2023341
2024310
2025168
202684

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,511 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
keratic precipitatesSignal2174853.44063.7569,194
anterior chamber cellSignal2332795.22398.6436,575
retinal vasculitisSignal3842745.82442.4712,089
vitreous opacitiesSignal2232068.81781.5337,759
vitritisSignal3581381.81237.1397,459
vitreous floatersSignal558347.0320.6181,336
eye inflammationSignal447283.3259.1119,653
uveitisSignal364159.0144.055,484
visual acuity reducedSignal43576.570.031,968
blindnessSignal24735.231.28,130
eye painSignal31932.829.59,767
ocular hyperaemiaSignal22427.324.15,644
visual impairmentSignal57326.824.814,212
vision blurredSignal53622.620.911,068
drug ineffective2211.00.90

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.